| abstract |
Lotteprednol etabonate, which has excellent anti-inflammatory and anti-allergic activities, is expected to be developed as a drug for external use, but when formulated in an aqueous suspension, it leads to aggregation and precipitation of particles. According to the present invention, long-term stabilization of suspensions is successfully achieved by formulating loteprednol etabonate with sodium caramel cellulose microcrystals. Moreover, the resulting suspension shows a significant improvement in intranasal retention and the absence of dermal or mucosal irritation. precipitation of particles tend to take place. According to the present invention, long-term stabilization of the suspension was successfully achieved by formulating loteprednol etabonate with microcrystalline cellulose carmellose sodium. Moreover, the resulting suspension features a remarkably improved intranasal retention and no dermal or mucosal irritation. |